Author:
Cook-Deegan Robert,Chandrasekharan Subhashini
Abstract
Whether, and to what degree, do patents granted on human genes cast a shadow of uncertainty over genomics and its applications? Will owners of patents on individual genes or clusters of genes sue those performing whole-genome analyses on human samples for patent infringement? These are related questions that have haunted molecular diagnostics companies and services, coloring scientific, clinical, and business decisions. Can the profusion of whole-genome analysis methods proceed without fear of patent infringement liability?Whole-genome sequencing (WGS) is proceeding apace. Academic centers have been performing whole-genome and -exome sequencing (WES) in research for at least five years, and academic clinical laboratories with national reach have been doing sequencing for clinical applications for almost as long. Companies have also been offering WGS and WES as a clinical service for a few years now. So far as we know, no one has been sued for infringement of “gene patents” for performing WGS.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects
Reference31 articles.
1. 29. Myriad Genetics Notice of Appeal to Court of Appeals for the Federal Circuit, Case: 14–1361 Document: 2–1, U.S. Court of Appeals for the Federal Circuit, 2014.
2. 31. See supra note 29.
3. 28. Memorandum decision and order denying plaintiffs motion for preliminary injunction, Case 2:13-cv-00640-RJS Document 185, U.S. District Court for Utah, 2014.
4. Can Patents Deter Innovation? The Anticommons in Biomedical Research
5. 22. Id.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献